Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

LY3023414 is an oral, selective adenosine triphosphate-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms, mammalian target of rapamycin, and DNA-protein kinase in clinical development. We report results of a 3 + 3 dose-escalation Phase 1 study for twice-daily (BID) dosing of LY...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Invest New Drugs
Main Authors: Kondo, Shunsuke, Tajimi, Masaomi, Funai, Tomohiko, Inoue, Koichi, Asou, Hiroya, Ranka, Vinay Kumar, Wacheck, Volker, Doi, Toshihiko
Formáid: Artigo
Teanga:Inglês
Foilsithe: Springer US 2020
Ábhair:
Phase I Studies
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7575488/
https://ncbi.nlm.nih.gov/pubmed/32578154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00968-5
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla